September 24th 2025
Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.
New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.
Read More
Evaluating the Efficacy of TMS for the Treatment of OCD
Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.
Read More